Logo image of CANF

CAN FITE BIOPHARMA LTD-ADR (CANF) Stock Fundamental Analysis

NYSEARCA:CANF - NYSE Arca - US13471N3008 - ADR - Currency: USD

1.06  +0.02 (+1.92%)

Fundamental Rating

3

CANF gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. CANF scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CANF is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CANF had negative earnings in the past year.
CANF had a negative operating cash flow in the past year.
In the past 5 years CANF always reported negative net income.
CANF had a negative operating cash flow in each of the past 5 years.
CANF Yearly Net Income VS EBIT VS OCF VS FCFCANF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

The Return On Assets of CANF (-86.40%) is worse than 72.61% of its industry peers.
CANF has a worse Return On Equity (-144.96%) than 61.80% of its industry peers.
Industry RankSector Rank
ROA -86.4%
ROE -144.96%
ROIC N/A
ROA(3y)-90.8%
ROA(5y)-101.33%
ROE(3y)-164.91%
ROE(5y)-170%
ROIC(3y)N/A
ROIC(5y)N/A
CANF Yearly ROA, ROE, ROICCANF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

CANF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CANF Yearly Profit, Operating, Gross MarginsCANF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

6

2. Health

2.1 Basic Checks

CANF does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CANF has more shares outstanding
The number of shares outstanding for CANF has been increased compared to 5 years ago.
There is no outstanding debt for CANF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CANF Yearly Shares OutstandingCANF Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
CANF Yearly Total Debt VS Total AssetsCANF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

CANF has an Altman-Z score of -25.31. This is a bad value and indicates that CANF is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -25.31, CANF is not doing good in the industry: 87.75% of the companies in the same industry are doing better.
There is no outstanding debt for CANF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -25.31
ROIC/WACCN/A
WACC9.07%
CANF Yearly LT Debt VS Equity VS FCFCANF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

CANF has a Current Ratio of 4.38. This indicates that CANF is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.38, CANF is in line with its industry, outperforming 48.47% of the companies in the same industry.
CANF has a Quick Ratio of 4.38. This indicates that CANF is financially healthy and has no problem in meeting its short term obligations.
CANF has a Quick ratio (4.38) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.38
Quick Ratio 4.38
CANF Yearly Current Assets VS Current LiabilitesCANF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

CANF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.00%, which is quite impressive.
Looking at the last year, CANF shows a decrease in Revenue. The Revenue has decreased by -9.29% in the last year.
The Revenue for CANF have been decreasing by -19.81% on average. This is quite bad
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-227.27%
Revenue 1Y (TTM)-9.29%
Revenue growth 3Y-7.55%
Revenue growth 5Y-19.81%
Sales Q2Q%14.04%

3.2 Future

CANF is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 50.44% yearly.
CANF is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 203.73% yearly.
EPS Next Y13.95%
EPS Next 2Y50.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0%
Revenue Next 2Y-10.92%
Revenue Next 3Y203.73%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CANF Yearly Revenue VS EstimatesCANF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
CANF Yearly EPS VS EstimatesCANF Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2023 2024 2025 2026 0 200 -200 -400 -600 -800

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CANF. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CANF. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CANF Price Earnings VS Forward Price EarningsCANF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CANF Per share dataCANF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -200 -400 -600

4.3 Compensation for Growth

A more expensive valuation may be justified as CANF's earnings are expected to grow with 50.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.44%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CANF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAN FITE BIOPHARMA LTD-ADR

NYSEARCA:CANF (6/30/2025, 2:47:35 PM)

1.06

+0.02 (+1.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26 2025-03-26/bmo
Earnings (Next)08-28 2025-08-28
Inst Owners4.05%
Inst Owner Change14.77%
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap13.65M
Analysts82.5
Price Target8.32 (684.91%)
Short Float %0.6%
Short Ratio0.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.35%
PT rev (3m)3.78%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)53.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 20.25
P/FCF N/A
P/OCF N/A
P/B 2.51
P/tB 2.51
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-710.06
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0.05
BVpS0.42
TBVpS0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -86.4%
ROE -144.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.8%
ROA(5y)-101.33%
ROE(3y)-164.91%
ROE(5y)-170%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 71.43%
Cap/Sales 0.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.38
Quick Ratio 4.38
Altman-Z -25.31
F-Score2
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)49.68%
Cap/Depr(5y)88.86%
Cap/Sales(3y)0.71%
Cap/Sales(5y)1.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-227.27%
EPS Next Y13.95%
EPS Next 2Y50.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-9.29%
Revenue growth 3Y-7.55%
Revenue growth 5Y-19.81%
Sales Q2Q%14.04%
Revenue Next Year0%
Revenue Next 2Y-10.92%
Revenue Next 3Y203.73%
Revenue Next 5YN/A
EBIT growth 1Y0.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.51%
OCF growth 3YN/A
OCF growth 5YN/A